The role of innate and lymphoid IL-22-producing cells in the immunopathology of primary Sjögren's syndrome

References

• Talal N, Sylvester RA, Daniels TE, et al. T and B lymphocytes in peripheral blood and tissue lesions in Sjögren's syndrome. J Clin Invest 1974;53(1):180-9
   PubMed Web of Science ®Google Scholar
• Mavragani CP, Moutsopoulos HM. Sjögren's Syndrome. Annu Rev Pathol 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Liang Y, Yang Z, Qin B, Zhong R. Primary Sjögren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Ohyama Y, Nakamura S, Matsuzaki G, et al. Cytokine messenger RNA expression in the labial salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 1996;39(8):1376-84
   PubMedGoogle Scholar
• Fox RI, Kang HI, Ando D, et al. Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome. J Immunol 1994;152(11):5532-9
   PubMed Web of Science ®Google Scholar
• van Woerkom JM, Kruize AA, Wenting-van Wijk MJ, et al. Salivary gland and peripheral blood T helper 1 and 2 cell activity in Sjögren's syndrome compared with non-Sjögren's sicca syndrome. Ann Rheum Dis 2005;64(10):1474-9
   PubMed Web of Science ®Google Scholar
• Katsifis GE, Rekka S, Moutsopoulos NM, et al. Systemic and local interleukin-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesis. Am J Pathol 2009;175(3):1167-77
   PubMed Web of Science ®Google Scholar
• Nguyen CQ, Hu MH, Li Y, et al. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjögren's syndrome: findings in humans and mice. Arthritis Rheum 2008;58(3):734-43
   PubMed Web of Science ®Google Scholar
• Moutsopoulos HM, Chused TM, Johnson AH, et al. B lymphocyte antigens in sicca syndrome. Science 1978;199(4336):1441-2
   PubMed Web of Science ®Google Scholar
• Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 2002;109(1):59-68
   PubMed Web of Science ®Google Scholar
• Rusakiewicz S, Nocturne G, Lazure T, et al. NCR3/NKp30 contributes to pathogenesis in primary Sjögren's syndrome. Sci Transl Med 2013;5(195):195ra196
   Web of Science ®Google Scholar
• Manoussakis MN, Dimitriou ID, Kapsogeorgou EK, et al. Expression of B7 costimulatory molecules by salivary gland epithelial cells in patients with Sjögren's syndrome. Arthritis Rheum 1999;42(2):229-39
   PubMedGoogle Scholar
• Xanthou G, Polihronis M, Tzioufas AG, et al. "Lymphoid" chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sjögren's syndrome patients: possible participation in lymphoid structure formation. Arthritis Rheum 2001;44(2):408-18
   PubMed Web of Science ®Google Scholar
• Barone F, Bombardieri M, Rosado MM, et al. CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjögren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. J Immunol 2008;180(7):5130-40
   PubMed Web of Science ®Google Scholar
• Sugimoto K, Ogawa A, Mizoguchi E, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008;118(2):534-44
   PubMed Web of Science ®Google Scholar
• Aujla SJ, Chan YR, Zheng M, et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 2008;14(3):275-81
   PubMed Web of Science ®Google Scholar
• Ciccia F, Accardo-Palumbo A, Alessandro R, et al. Interleukin-22 and IL-22-producing NKp44(+) NK cells in the subclinical gut inflammation of patients with ankylosing spondylitis. Arthritis Rheum 2012;64(6):1869-78
   PubMed Web of Science ®Google Scholar
• Ikeuchi H, Kuroiwa T, Hiramatsu N, et al. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum 2005;52(4):1037-46
   PubMedGoogle Scholar
• Bard JD, Gelebart P, Anand M, et al. Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma. Leukemia 2008;22(8):1595-603
   PubMed Web of Science ®Google Scholar
• Gelebart P, Zak Z, Dien-Bard J, et al. Interleukin 22 signaling promotes cell growth in mantle cell lymphoma. Transl Oncol 2011;4(1):9-19
   PubMed Web of Science ®Google Scholar
• Rutz S, Eidenschenk C, Ouyang W. IL-22, not simply a Th17 cytokine. Immunol Rev 2013;252(1):116-32
   PubMed Web of Science ®Google Scholar
• Sonnenberg GF, Nair MG, Kirn TJ, et al. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J Exp Med 2010;207(6):1293-305
   PubMed Web of Science ®Google Scholar
• Lavoie TN, Stewart CM, Berg KM, et al. Expression of interleukin-22 in Sjögren's syndrome: significant correlation with disease parameters. Scand J Immunol 2011;74(4):377-82
   PubMed Web of Science ®Google Scholar
• Ciccia F, Guggino G, Rizzo A, et al. Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjögren's syndrome. Ann Rheum Dis 2012;71(2):295-301
   PubMed Web of Science ®Google Scholar
• Ouyang W, Rutz S, Crellin NK, et al. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 2011;29:71-109
   PubMed Web of Science ®Google Scholar
• Dumoutier L, Van Roost E, Colau D, Renauld JC. Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor. Proc Natl Acad Sci USA 2000;97(18):10144-9
   PubMed Web of Science ®Google Scholar
• Xie MH, Aggarwal S, Ho WH, et al. Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J Biol Chem 2000;275(40):31335-9
   PubMed Web of Science ®Google Scholar
• Kotenko SV, Izotova LS, Mirochnitchenko OV, et al. Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J Biol Chem 2001;276(4):2725-32
   PubMed Web of Science ®Google Scholar
• Wolk K, Kunz S, Witte E, et al. IL-22 increases the innate immunity of tissues. Immunity 2004;21(2):241-54
   PubMed Web of Science ®Google Scholar
• Lécart S, Morel F, Noraz N, et al. IL-22, in contrast to IL-10, does not induce Ig production, due to absence of a functional IL-22 receptor on activated human B cells. Int Immunol 2002;14(11):1351-6
   PubMed Web of Science ®Google Scholar
• Nagalakshmi ML, Rascle A, Zurawski S, et al. Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. Int Immunopharmacol 2004;4(5):679-91
   PubMed Web of Science ®Google Scholar
• Lejeune D, Dumoutier L, Constantinescu S, et al. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem 2002;277(37):33676-82
   PubMed Web of Science ®Google Scholar
• Dumoutier L, Lejeune D, Colau D, Renauld JC. Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22. J Immunol 2001;166(12):7090-5
   PubMed Web of Science ®Google Scholar
• Huber S, Gagliani N, Zenewicz LA, et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 2012;491(7423):259-63
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 Binding Protein. Front Immunol 2013;4:289
   PubMed Web of Science ®Google Scholar
• Bombardieri M, Barone F, Pittoni V, et al. Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjögren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate. Arthritis Res Ther 2004;6(5):R447-56
   PubMed Web of Science ®Google Scholar
• Gurney AL. IL-22, a Th1 cytokine that targets the pancreas and select other peripheral tissues. Int Immunopharmacol 2004;4(5):669-77
   PubMed Web of Science ®Google Scholar
• Sutton CE, Lalor SJ, Sweeney CM, et al. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 2009;31(2):331-41
   PubMed Web of Science ®Google Scholar
• Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007;445(7128):648-51
   PubMed Web of Science ®Google Scholar
• Wolk K, Kunz S, Asadullah K, Sabat R. Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol 2002;168(11):5397-402
   PubMed Web of Science ®Google Scholar
• Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006;203(10):2271-9
   PubMed Web of Science ®Google Scholar
• Duhen T, Geiger R, Jarrossay D, et al. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009;10(8):857-63
   PubMed Web of Science ®Google Scholar
• Trifari S, Kaplan CD, Tran EH, et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009;10(8):864-71
   PubMed Web of Science ®Google Scholar
• Ortega C, Fernández-A S, Carrillo JM, et al. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol 2009;86(2):435-43
   PubMed Web of Science ®Google Scholar
• Martin B, Hirota K, Cua DJ, et al. Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. Immunity 2009;31(2):321-30
   PubMed Web of Science ®Google Scholar
• Goto M, Murakawa M, Kadoshima-Yamaoka K, et al. Murine NKT cells produce Th17 cytokine interleukin-22. Cell Immunol 2009;254(2):81-4
   PubMed Web of Science ®Google Scholar
• Doisne JM, Soulard V, Bécourt C, et al. Cutting edge: crucial role of IL-1 and IL-23 in the innate IL-17 response of peripheral lymph node NK1.1- invariant NKT cells to bacteria. J Immunol 2011;186(2):662-6
   PubMed Web of Science ®Google Scholar
• Crellin NK, Trifari S, Kaplan CD, et al. Human NKp44+IL-22+ cells and LTi-like cells constitute a stable RORC+ lineage distinct from conventional natural killer cells. J Exp Med 2010;207(2):281-90
   PubMed Web of Science ®Google Scholar
• Cupedo T, Crellin NK, Papazian N, et al. Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells. Nat Immunol 2009;10(1):66-74
   PubMed Web of Science ®Google Scholar
• Cella M, Fuchs A, Vermi W, et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 2009;457(7230):722-5
   PubMed Web of Science ®Google Scholar
• Ahn YO, Blazar BR, Miller JS, Verneris MR. Lineage relationships of human interleukin-22-producing CD56+ RORγt+ innate lymphoid cells and conventional natural killer cells. Blood 2013;121(12):2234-43
   PubMed Web of Science ®Google Scholar
• Qiu J, Guo X, Chen ZM, et al. Group 3 innate lymphoid cells inhibit T-cell-mediated intestinal inflammation through aryl hydrocarbon receptor signaling and regulation of microflora. Immunity 2013;39(2):386-99
   PubMed Web of Science ®Google Scholar
• Zelante T, Iannitti RG, Cunha C, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 2013;39(2):372-85
   PubMed Web of Science ®Google Scholar
• Leppkes M, Becker C, Ivanov II, et al. RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 2009;136(1):257-67
   PubMed Web of Science ®Google Scholar
• Wolk K, Witte E, Wallace E, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006;36(5):1309-23
   PubMed Web of Science ®Google Scholar
• Boniface K, Guignouard E, Pedretti N, et al. A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol 2007;150(3):407-15
   PubMed Web of Science ®Google Scholar
• Zheng Y, Valdez PA, Danilenko DM, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 2008;14(3):282-9
   PubMed Web of Science ®Google Scholar
• Liang SC, Nickerson-Nutter C, Pittman DD, et al. IL-22 induces an acute-phase response. J Immunol 2010;185(9):5531-8
   PubMed Web of Science ®Google Scholar
• Croxford AL, Mair F, Becher B. IL-23: one cytokine in control of autoimmunity. Eur J Immunol 2012;42(9):2263-73
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, Yang XP, et al. T helper 17 cell heterogeneity and pathogenicity in autoimmune disease. Trends Immunol 2011;32(9):395-401
   PubMed Web of Science ®Google Scholar
• Glatzer T, Killig M, Meisig J, et al. RORγt+ innate lymphoid cells acquire a proinflammatory program upon engagement of the activating receptor NKp44. Immunity 2013;38(6):1223-35
   PubMed Web of Science ®Google Scholar
• Savan R, McFarland AP, Reynolds DA, et al. A novel role for IL-22R1 as a driver of inflammation. Blood 2011;117(2):575-84
   PubMed Web of Science ®Google Scholar
• Ciccia F, Alessandro R, Rizzo A, et al. Expression of interleukin-32 in the inflamed arteries of patients with giant cell arteritis. Arthritis Rheum 2011;63(7):2097-104
   PubMedGoogle Scholar
• Eun YG, Shin IH, Lee YC, et al. Interleukin 22 polymorphisms and papillary thyroid cancer. J Endocrinol Invest 2013;36(8):584-7
   PubMed Web of Science ®Google Scholar
• Thompson CL, Plummer SJ, Tucker TC, et al. Interleukin-22 genetic polymorphisms and risk of colon cancer. Cancer Causes Control 2010;21(8):1165-70
   PubMed Web of Science ®Google Scholar
• Beyeen AD, Adzemovic MZ, Ockinger J, et al. IL-22RA2 associates with multiple sclerosis and macrophage effector mechanisms in experimental neuroinflammation. J Immunol 2010;185(11):6883-90
   PubMed Web of Science ®Google Scholar
• Endam LM, Bossé Y, Filali-Mouhim A, et al. Polymorphisms in the interleukin-22 receptor alpha-1 gene are associated with severe chronic rhinosinusitis. Otolaryngol Head Neck Surg 2009;140(5):741-7
   PubMed Web of Science ®Google Scholar
• Suh JS, Cho SH, Chung JH, et al. A polymorphism of interleukin-22 receptor alpha-1 is associated with the development of childhood IgA nephropathy. J Interferon Cytokine Res 2013;33(10):571-7
   PubMed Web of Science ®Google Scholar
• Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62(4):960-8
   PubMed Web of Science ®Google Scholar
• Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 2005;52(9):2740-50
   PubMedGoogle Scholar
• Ciccia F, Giardina A, Rizzo A, et al. Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjögren's syndrome. Ann Rheum Dis 2013;72(5):782-3
   PubMed Web of Science ®Google Scholar
• Long EO, Kim HS, Liu D, et al. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 2013;31:227-58
   PubMed Web of Science ®Google Scholar
• Hughes T, Becknell B, Freud AG, et al. Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue. Immunity 2010;32(6):803-14
   PubMed Web of Science ®Google Scholar
• Kumar P, Thakar MS, Ouyang W, Malarkannan S. IL-22 from conventional NK cells is epithelial regenerative and inflammation protective during influenza infection. Mucosal Immunol 2013;6(1):69-82
   PubMed Web of Science ®Google Scholar
• Dhiman R, Indramohan M, Barnes PF, et al. IL-22 produced by human NK cells inhibits growth of Mycobacterium tuberculosis by enhancing phagolysosomal fusion. J Immunol 2009;183(10):6639-45
   PubMed Web of Science ®Google Scholar
• Li H, Ice JA, Lessard CJ, Sivils KL. Interferons in Sjögren's Syndrome: genes, Mechanisms, and Effects. Front Immunol 2013;4:290
   PubMed Web of Science ®Google Scholar
• Nguyen CQ, Peck AB. The Interferon-Signature of Sjögren's Syndrome: how Unique Biomarkers Can Identify Underlying Inflammatory and Immunopathological Mechanisms of Specific Diseases. Front Immunol 2013;4:142
   PubMed Web of Science ®Google Scholar
• Minato N, Takeda A, Kano S, Takaku F. Studies of the function of natural killer-interferon system in patients with Sjögren syndrome. J Clin Invest 1982;69(3):581-8
   PubMed Web of Science ®Google Scholar
• Miyasaka N, Seaman W, Bakshi A, et al. Natural killing activity in Sjögren's syndrome. An analysis of defective mechanisms. Arthritis Rheum 1983;26(8):954-60
   PubMedGoogle Scholar
• Pedersen BK, Oxholm P, Manthorpe R, Andersen V. Interleukin 2 augmentation of the defective natural killer cell activity in patients with primary Sjögren's syndrome. Clin Exp Immunol 1986;63(1):1-7
   PubMed Web of Science ®Google Scholar
• Takeda A, Minato N, Kano S. Selective impairment of alpha-interferon-mediated natural killer augmentation in Sjögren's syndrome: differential effects of alpha-interferon, gamma-interferon, and interleukin 2 on cytolytic activity. Clin Exp Immunol 1987;70(2):354-63
   PubMed Web of Science ®Google Scholar
• Izumi Y, Ida H, Huang M, et al. Characterization of peripheral natural killer cells in primary Sjögren's syndrome: impaired NK cell activity and low NK cell number. J Lab Clin Med 2006;147(5):242-9
   PubMed Web of Science ®Google Scholar
• Vivier E, Biron CA. Immunology. A pathogen receptor on natural killer cells. Science 2002;296(5571):1248-9
   PubMed Web of Science ®Google Scholar
• Vitale M, Della Chiesa M, Carlomagno S, et al. NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood 2005;106(2):566-71
   PubMed Web of Science ®Google Scholar
• Okuma A, Hoshino K, Ohba T, et al. Enhanced apoptosis by disruption of the STAT3-IκB-ζ signaling pathway in epithelial cells induces Sjögren's syndrome-like autoimmune disease. Immunity 2013;38(3):450-60
   PubMed Web of Science ®Google Scholar
• Baker OJ. Tight junctions in salivary epithelium. J Biomed Biotechnol 2010;2010:278948
   PubMedGoogle Scholar
• Guillot C, Lecuit T. Mechanics of epithelial tissue homeostasis and morphogenesis. Science 2013;340(6137):1185-9
   PubMed Web of Science ®Google Scholar
• Shen L, Weber CR, Raleigh DR, et al. Tight junction pore and leak pathways: a dynamic duo. Annu Rev Physiol 2011;73:283-309
   PubMed Web of Science ®Google Scholar
• Ewert P, Aguilera S, Alliende C, et al. Disruption of tight junction structure in salivary glands from Sjögren's syndrome patients is linked to proinflammatory cytokine exposure. Arthritis Rheum 2010;62(5):1280-9
   PubMedGoogle Scholar
• Odusanwo O, Chinthamani S, McCall A, et al. Resolvin D1 prevents TNF-α-mediated disruption of salivary epithelial formation. Am J Physiol Cell Physiol 2012;302(9):C1331-45
   PubMed Web of Science ®Google Scholar
• Goicovich E, Molina C, Pérez P, et al. Enhanced degradation of proteins of the basal lamina and stroma by matrix metalloproteinases from the salivary glands of Sjögren's syndrome patients: correlation with reduced structural integrity of acini and ducts. Arthritis Rheum 2003;48(9):2573-84
   PubMedGoogle Scholar